高级检索
当前位置: 首页 > 详情页

Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China [2]Peking Univ, Dept Rheumatol & Immunol, Shougang Hosp, Beijing 100044, Peoples R China [3]Shanxi Med Univ, Dept Rheumatol & Immunol, Affiliated Hosp 2, Taiyuan, Shanxi, Peoples R China [4]Baotou Med Coll, Dept Rheumatol & Immunol, Affiliated Hosp 1, Baotou, Inner Mongolia, Peoples R China [5]China Japan Friendship Hosp, Dept Rheumatol, Beijing, Peoples R China [6]Fourth Mil Med Univ, Dept Rheumatol & Immunol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China [7]Hebei Med Univ, Dept Rheumatol & Immunol, Hosp 2, Shijiazhuang, Hebei, Peoples R China [8]Hebei Med Univ, Dept Rheumatol & Immunol, Hosp 3, Shijiazhuang, Hebei, Peoples R China [9]Peking Univ, Dept Rheumatol & Immunol, Hosp 3, Beijing 100044, Peoples R China [10]North China Coal Med Univ, Dept Rheumatol & Immunol, Affiliated Kailuan Hosp, Tangshan, Hebei, Peoples R China [11]Peking Univ, Dept Rheumatol & Immunol, Hosp 1, Beijing 100044, Peoples R China [12]Bethune Int Peace Hosp, Dept Rheumatol & Immunol, Shijiazhuang, Hebei, Peoples R China [13]Cent Hosp Handan City, Dept Rheumatol & Immunol, Handan, Hebei, Peoples R China [14]Hebei Peoples Hosp, Dept Rheumatol & Immunol, Shijiazhuang, Hebei, Peoples R China [15]Peoples Hosp Guangxi, Dept Rheumatol & Immunol, Nanning, Guangxi, Peoples R China [16]China Med Univ, Dept Rheumatol & Immunol, Beijing Shunyi Hosp, Beijing, Peoples R China [17]Huazhong Univ Sci & Technol, Dept Rheumatol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China [18]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, Guangzhou 510275, Guangdong, Peoples R China [19]Beijing Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China [20]Shandong Univ, Dept Rheumatol, Qilu Hosp, Jinan, Shandong, Peoples R China [21]Cangzhou Hosp Integrated Tradit Chinese & Western, Dept Rheumatol & Immunol, Cangzhou, Hebei, Peoples R China [22]Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Rheumatol & Immunol, Urumqi, Xinjiang, Peoples R China [23]Xi An Jiao Tong Univ, Dept Rheumatol & Immunol, Affiliated Hosp 1, Xian 710049, Shaanxi, Peoples R China [24]Tianjin Med Univ, Dept Infect Dis & Rheumatol, Gen Hosp, Tianjin, Peoples R China [25]Lanzhou Univ, Dept Rheumatol, Hosp 2, Lanzhou 730000, Gansu, Peoples R China [26]Beijing Xuanwu Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China [27]Lanzhou Univ, Dept Rheumatol & Immunol, Affiliated Hosp 5, Lanzhou 730000, Gansu, Peoples R China [28]309th Hosp Chinese Peoples Liberat Army, Dept Rheumatol & Immunol, Beijing, Peoples R China [29]Peking Univ, Dept Clin Epidemiol, Peoples Hosp, Beijing 100044, Peoples R China
出处:
ISSN:

关键词: Cross-sectional study Remission Rheumatoid arthritis Risk factors

摘要:
The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July 2009 to January 2012. Data were collected by face-to-face interviews of the rheumatology outpatients in 28 tertiary hospitals in China. The remission rates were calculated in 486 RA patients according to different definitions of remission: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definition. Potential determinants of RA remission were assessed by univariate and multivariate analyses. The remission rates of RA from this multi-center cohort were 8.6 % (DAS28), 8.4 % (SDAI), 8.2 % (CDAI), and 6.8 % (Boolean), respectively. Favorable factors associated with remission were: low Health Assessment Questionnaire (HAQ) score, absence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and treatment of methotrexate (MTX) and hydroxychloroquine (HCQ). Younger age was also predictive for the DAS28 and the Boolean remission. Multivariate analyses revealed a low HAQ score, the absence of anti-CCP, and the treatment with HCQ as independent determinants of remission. The clinical remission rate of RA patients was low in China. A low HAQ score, the absence of anti-CCP, and HCQ were significant independent determinants for RA remission.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 风湿病学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 风湿病学
JCR分区:
出版当年[2013]版:
Q3 RHEUMATOLOGY
最新[2023]版:
Q2 RHEUMATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者单位: [1]Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China
通讯作者:
通讯机构: [1]Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China [*1]Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)